Editing Cyclooxygenase (section)

=== Newer NSAIDs ===
Selectivity for COX-2 is the main feature of [[celecoxib]], [[etoricoxib]], and other members of this drug class.  Because COX-2 is usually specific to inflamed tissue, there is much less gastric irritation associated with COX-2 inhibitors, with a decreased risk of peptic ulceration. The selectivity of COX-2 does not seem to negate other side-effects of NSAIDs, most notably an increased risk of [[kidney failure]], and there is evidence that indicates an increase in the risk of [[myocardial infarction|heart attack]], [[thrombosis]], and [[stroke]] through an increase of [[thromboxane]] unbalanced by prostacyclin (which is reduced by COX-2 inhibition).<ref>Kumar, V., Abbas, A. K., & Aster, J. C. (2017). Robbins Basic Pathology (10th ed.). Elsevier - Health Sciences Division.
</ref>  [[Rofecoxib]] (brand name [[Vioxx]]) was withdrawn in 2004 because of such concerns. Some other COX-2 selective NSAIDs, such as [[celecoxib]], and etoricoxib, are still on the market.